mVOCAL: Mobile Video Interpretation to Optimize Communication Across Language Barriers
Study Details
Study Description
Brief Summary
Patients and families with limited English proficiency (LEP) and/or who use a language other than English for medical care (LOE) experience substantial barriers to communication in the healthcare setting, leading to medical care that is less safe, less efficient, less effective, and inequitable. Professional interpreter use has repeatedly been shown to improve outcomes and reduce disparities, yet it remains widely underused. This study will test two discrete, scalable implementation strategies for improving professional interpreter use in primary care, while collecting detailed information about mechanisms of action and costs that will be applicable to many sites of care and contribute meaningfully to the goal of reducing communication-based disparities. We hypothesize that improving provider knowledge, confidence, and interpreter access will change behavior under real-world conditions.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This study will be conducted over a series of 4 phases.
Phase 0 (15 months): We will enroll 55 primary care providers from 4-8 enrolled clinics within the WWAMI region Practice and Research network (WPRN) or similar primary care practices. Enrolled providers will complete a baseline survey and a baseline in-depth qualitative interview, exploring baseline barriers, facilitators, moderators, necessary prerequisites, and proximal outcomes of professional interpreter use in their current clinic setting. Providers will receive a gift card for completing the survey and a gift card for completing the 30-60 minute interview. During this phase we will calculate baseline interpreter use for each enrolled provider by matching interpreter vendor invoice data to visits with patients listed as preferring a language other than English for medical care over the past 6 months.
Phase 1 (9 months): We will randomize enrolled providers 1:1 to either web-based educational modules or mobile video interpreting (mVI), stratified by clinic and baseline interpreter use. For education-assigned providers, they will receive access to the online modules and begin receiving weekly reminder emails. They will also receive a tip sheet for making the best use of the current interpreter services they have access to in their clinic. mVI-assigned providers will have mVI downloaded onto their preferred device (smartphone or tablet), or be issued a study smartphone if they do not want to use their own. They will be shown how to use it and receive a tip sheet for optimal mVI use in clinic. We will then begin 9 months of data collection for phase 1.
In addition to tracking interpreter use, we will also begin recruiting patients or parents of pediatric patients with LOE to participate in one of 3 data collection activities. We will enroll patients or parents of pediatric patients who are being seen by an enrolled provider for an acute concern and who prefer one of the top 4 non-English languages in the area (likely Spanish, Mandarin, Vietnamese, or Arabic, but to be finalized when all clinics enrolled) to complete a post-visit survey (n=648 total; 324 during phase 1). Patients will be approached by telephone before the visit or in-person in the waiting room prior to the clinic visit, then the survey will be administered immediately after the visit. The survey will collect patient reported communication quality, interpretation satisfaction, demographic information, and patient reported diagnosis. The survey will be administered via REDCap, using an audio feature that will allow participants to read or listen to the survey questions in their preferred language for care. Patients will receive a gift card for completing the survey. Patients who report a concern about how communication occurred on the survey, along with a randomly-selected subset of others, will be invited to complete a 20 to 30 minutes interview to provide greater detail about how communication and interpretation occurred and what their experience of it was like (n=75 total, 38 during Phase 1). Whenever possible, the interview will be completed immediately after the survey, while the patient or family is still in the clinic. If the patient wishes to participate but they are unable to stay or their language is different than the bilingual research coordinator's, the interview will be conducted over the telephone within 3 days of the clinic visit. The interview will be conducted by a research coordinator bilingual in the patient's preferred language. Patients will receive a gift card for completing the interview.
We will also be requesting permission to video record a subset of patient visits (n=100 total, 50 during Phase 1). Video recording will occur over a 3 to 4-week block of time in each clinic during each of Phases 1 and 2. Patients or parents of pediatric patients who prefer one of the top of 4 non-English languages and are being seen by an enrolled provider for any visit reason will be eligible and approached in the waiting room prior to the clinic visit. Those who consent to video recording will have a video camera mounted in the corner of the patient room and will have their encounter video-recorded.
During Phase 1, providers that will complete a 2nd in-depth qualitative interview, revisiting some of the barriers, facilitators, moderators, necessary prerequisites, and proximal outcomes from the 1st interview, and assessing experiences and perceived change in behavior with the assigned strategy. They will receive a gift card for completing the 30-60 minute interview.
Phase 2 (9 months): At the beginning of phase 2 we will calculate interpreter use for enrolled providers during Phase 1. Providers will be rank-ordered by interpreter use within assigned strategy. Those with interpreter use in the top tertile will receive an email of positive feedback and be encouraged to continue with their originally assigned strategy. Providers with interpreter use in the lowest two tertiles will undergo a 2nd round of randomization, either to continue with the originally assigned strategy or to add the 2nd strategy on top of the 1st. Those assigned to continue with the initially assigned strategy will receive a brief check-in from study staff to be sure they know how to access and interact with their assigned strategy. Those assigned to the 2nd strategy will receive access to it, as described above.
Patient data collection will continue as described for Phase 1, with ongoing recruitment for patient surveys (n=324 for Phase 2), interviews (n=37 for Phase 2), and video recording (n=50 for Phase 2).
Providers will complete a 3rd in-depth interview during Phase 2, again assessing barriers, facilitators, moderators, necessary prerequisites, and proximal outcomes from the 1st interview, and eliciting experiences and perceived change in behavior with the assigned strategy or strategies. They will receive a gift card for completing the 30-60 minute interview.
During Phase 2, we will begin abstracting provider-reported diagnosis from clinic visit chart notes for patients who completed the survey. Abstraction will be completed by a trained abstractor, blinded to provider assigned strategy, and continue into Phase 3.
Diagnosis concordance coding will begin at the end of Phase 2. Two trained coders will compare patient-reported diagnosis (collected through the survey and professionally translated into English) to provider-documented diagnosis (abstracted from the chart). Each pair will be coded as yes, concordant; no, not concordant; or unclear/insufficient information, using the standard of whether a follow-up provider would be likely to understand what the patient was seen or treated for based on the information provided by the patient. Disagreements will be resolved through discussion, with input from the PI as needed. All coders will be blinded to provider assigned strategy and patient information during the coding process.
Coding of qualitative interviews and video recordings will also begin at the end of Phase 2. These will be conducted by trained research coordinators, under the supervision of study investigators.
Phase 3 (9 months): During phase 3, we will provide access to mVI and the educational modules for any enrolled providers who would like them. We will continue to measure interpreter use and will track uptake of both strategies by providers who were not initially assigned to them. We will not continue patient surveys, interviews, and video recording during this phase. Providers will be asked to complete a final survey, re-assessing constructs from the Theoretical Domains Framework that were measured at baseline, and eliciting time and out-of-pocket costs related to each strategy.
During phase 3, diagnosis chart abstraction will be completed, as will diagnosis concordance coding. Qualitative coding and analysis, and video recording coding and analysis will continue throughout phase 3.
During this phase, we will work with each clinic to develop a sustainment plan, informed by a review of the site-specific barriers to interpreter use identified in the final survey and interviews.
Phase 4 (18 months): This final study phase will be dedicated to analysis and results dissemination. Provider participation will be complete, and access to mVI and the educational modules for study purposes will be discontinued, although we will work with clinics to establish methods for ongoing access should the clinics wish to pursue this option.
Provider interpreter use during the 6 month follow-up period (Phase 3) will be calculated and shared with clinics. We will continue qualitative and video-recording coding and analysis, along with our quantitative analyses related to overall interpreter use, patient comprehension, and the cost-effectiveness of each strategy (mVI, education, or both) for improving interpreter use and patient comprehension.
During this time, we will also refine our preliminary causal pathway models, exploring potential mechanisms by which mVI and education may be operating to improve interpreter use and/or patient comprehension.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Web based educational modules This strategy will consist of 5 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 5 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be <15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete. |
Behavioral: Web based educational modules
This strategy will consist of 5 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 5 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be <15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
|
| Experimental: Mobile video interpreting access (mVI) This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices. |
Behavioral: mobile video interpreting (mVI) access
This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
|
Outcome Measures
Primary Outcome Measures
- Interpreter Use per Clinic Visit with Patient with LOE [at 9 months]
Dichotomous variable per visit for patients with a language other than English (LOE), constructed by matching professional interpreter vendor invoices to LOE clinic visits with enrolled providers; calculated overall and as assigned (e.g., mVI for mVI providers).
Secondary Outcome Measures
- Patient/Parent Comprehension [Within 7 days of the clinic visit]
Dichotomous variable coded as Yes vs No or Unclear, based on 2 blinded coders evaluating concordance between patient-reported and provider-documented diagnosis, against the standard of whether a follow-up provider would know the diagnosis based on the patient-reported information.
Eligibility Criteria
Criteria
Providers:
-
Primary clinical site at a participating clinic
-
Work at least 40% full-time equivalent as a primary care provider
-
needs interpretation for at least 7 visits per month
For LOE population 1 (administrative cohort):
-
preferred language for care listed as anything besides English or sign language (e.g., ASL)
-
clinic visit (any reason) during study with an enrolled provider
For LOE populations 2 and 3 (survey and interview respondents):
-
preferred language for care one of the top 4 non-English languages across enrolled clinics (listed in chart and confirmed by research coordinator)
-
clinic visit for an acute concern (e.g., sore throat, injured ankle, new headaches) during study with an enrolled provider
-
if patient under age 18, accompanied by a parent or legal guardian
For LOE population 4 (video-recording):
-
preferred language for care listed as anything besides English or sign language (e.g., ASL)
-
clinic visit for any reason during study with an enrolled provider
-
if patient under age 18, accompanied by a parent or legal guardian
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Seattle Children's | Seattle | Washington | United States | 98105 |
Sponsors and Collaborators
- Seattle Children's Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STUDY00003332